Roflumilast for asthma: Weighing the evidence

Pulm Pharmacol Ther. 2015 Dec:35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13.

¹ Division of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa. Electronic address: Eric.Bateman@uct.ac.za.
² Firestone Institute for Respiratory Health, Department of Medicine, McMaster University, Hamilton, Canada. Electronic address: obyrnep@mcmaster.ca.
³ Pulmonary Department, Mainz University Hospital, Mainz, Germany. Electronic address: Roland.Buhl@unimedizin-mainz.de.
⁴ LungClinic, Großhansdorf, Germany; Department of Medicine, Christian Albrecht University Kiel, Germany; Members of the German Center for Lung Research (DZL), Germany. Electronic address: k.f.rabe@lungenclinic.de.

No abstract available

Keywords: Asthma; FEV(1); ICS; Placebo; Roflumilast; Safety.

Publication types